文献速递心脑血管急症

高危患者PCI术后常规功能学检查与标准随访的随机对照研究

Routine Functional Testing or Standard Care in High-Risk Patients after PCI.
PubMed 文献 · N Engl J Med · 2022-08-28
一句话结论高危PCI术后1年常规功能学检查较标准随访未改善2年临床结局(5.5% vs 6.0%,HR 0.90,P=0.62)。

该随机对照试验纳入1706例具有高危解剖或临床特征且已行PCI的患者,随机分为PCI术后1年常规功能学检查组(核素负荷试验、运动心电图或负荷超声心动图)与单纯标准随访组。主要终点为2年全因死亡、心肌梗死或不稳定型心绞痛住院的复合终点,功能学检查组发生46/849例(Kaplan-Meier估计5.5%),标准随访组51/857例(6.0%),HR 0.90(95%CI 0.61-1.35),P=0.62,组间无差异。2年时功能学检查组12.3%接受侵入性冠状动脉造影,标准随访组9.3%(差值2.99个百分点,95%CI -0.01至5.99);重复血运重建分别为8.1%和5.8%(差值2.23个百分点,95%CI -0.22至4.68)。作者结论认为,高危PCI术后常规功能学检查随访策略较单纯标准随访未改善2年临床结局。

要点

  • 高危解剖或临床特征PCI术后患者,1年时常规功能学检查较标准随访未降低2年死亡、心肌梗死或不稳定型心绞痛住院复合终点(5.5% vs 6.0%,HR 0.90,95%CI 0.61-1.35,P=0.62)。
  • 主要终点各组分(全因死亡、心肌梗死、不稳定型心绞痛住院)组间均无差异。
  • 2年侵入性冠状动脉造影:功能学检查组12.3% vs 标准随访组9.3%,差值2.99个百分点(95%CI -0.01至5.99)。
  • 2年重复血运重建:功能学检查组8.1% vs 标准随访组5.8%,差值2.23个百分点(95%CI -0.22至4.68)。
  • 研究人群平均年龄64.7岁,21.0%左主干病变、43.5%分叉病变、69.8%多支病变、70.1%弥漫长病变、38.7%糖尿病,96.4%置入药物洗脱支架。

适用人群与场景

  • 具有高危解剖或临床特征且已行PCI的患者,随机分组时平均年龄64.7岁;21.0%左主干病变、43.5%分叉病变、69.8%多支病变、70.1%弥漫长病变、38.7%糖尿病,96.4%置入药物洗脱支架。

处置流程与药物剂量

  • 功能学检查随访组在PCI术后1年接受常规功能学检查,方式为核素负荷试验、运动心电图或负荷超声心动图。
  • 标准随访组仅接受单纯标准随访,不进行常规功能学检查。

研究设计与关键结果

  • 多中心随机对照试验,纳入1706例高危解剖或临床特征PCI术后患者,随机分为1年时常规功能学检查随访组(n=849)与单纯标准随访组(n=857)。
  • 主要终点为2年全因死亡、心肌梗死或不稳定型心绞痛住院复合终点:功能学检查组46/849例(Kaplan-Meier估计5.5%)vs 标准随访组51/857例(6.0%),HR 0.90(95%CI 0.61-1.35),P=0.62。
  • 主要终点各组分(全因死亡、心肌梗死、不稳定型心绞痛住院)组间均无差异。
  • 2年侵入性冠状动脉造影:功能学检查组12.3% vs 标准随访组9.3%,差值2.99个百分点(95%CI -0.01至5.99)。
  • 2年重复血运重建:功能学检查组8.1% vs 标准随访组5.8%,差值2.23个百分点(95%CI -0.22至4.68)。

证据类型、等级与局限

  • 证据类型:随机对照试验(POST-PCI,NCT03217877),由CardioVascular Research Foundation和Daewoong Pharmaceutical资助。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对于具有高危解剖或临床特征且已行PCI的患者,作者结论认为,与单纯标准随访相比,1年时常规功能学检查随访策略未改善2年临床结局。
  • 常规功能学检查随访组2年侵入性冠状动脉造影比例12.3%高于标准随访组9.3%(差值2.99个百分点,95%CI -0.01至5.99),重复血运重建比例8.1%高于标准随访组5.8%(差值2.23个百分点,95%CI -0.22至4.68)。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: There are limited data from randomized trials to guide a specific follow-up surveillance approach after myocardial revascularization. Whether a follow-up strategy that includes routine functional testing improves clinical outcomes among high-risk patients who have undergone percutaneous coronary intervention (PCI) is uncertain.

METHODS: We randomly assigned 1706 patients with high-risk anatomical or clinical characteristics who had undergone PCI to a follow-up strategy of routine functional testing (nuclear stress testing, exercise electrocardiography, or stress echocardiography) at 1 year after PCI or to standard care alone. The primary outcome was a composite of death from any cause, myocardial infarction, or hospitalization for unstable angina at 2 years. Key secondary outcomes included invasive coronary angiography and repeat revascularization.

RESULTS: The mean age of the patients was 64.7 years, 21.0% had left main disease, 43.5% had bifurcation disease, 69.8% had multivessel disease, 70.1% had diffuse long lesions, 38.7% had diabetes, and 96.4% had been treated with drug-eluting stents. At 2 years, a primary-outcome event had occurred in 46 of 849 patients (Kaplan-Meier estimate, 5.5%) in the functional-testing group and in 51 of 857 (Kaplan-Meier estimate, 6.0%) in the standard-care group (hazard ratio, 0.90; 95% confidence interval [CI], 0.61 to 1.35; P = 0.62). There were no between-group differences with respect to the components of the primary outcome. At 2 years, 12.3% of the patients in the functional-testing group and 9.3% in the standard-care group had undergone invasive coronary angiography (difference, 2.99 percentage points; 95% CI, -0.01 to 5.99), and 8.1% and 5.8% of patients, respectively, had undergone repeat revascularization (difference, 2.23 percentage points; 95% CI, -0.22 to 4.68).

CONCLUSIONS: Among high-risk patients who had undergone PCI, a follow-up strategy of routine functional testing, as compared with standard care alone, did not improve clinical outcomes at 2 years. (Funded by the CardioVascular Research Foundation and Daewoong Pharmaceutical; POST-PCI ClinicalTrials.gov number, NCT03217877.).

来源:N Engl J Med,查看原文。版权归原作者所有。

参考来源

  1. Park DW, Kang DY, Ahn JM, et al. Routine Functional Testing or Standard Care in High-Risk Patients after PCI. N Engl J Med. 2022. PMID: 36036496. doi:10.1056/NEJMoa2208335

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。